 - Documented progression of disease after initiation of therapy with OR lack of response to therapy with a PD-1- or PD-L1-targeting monoclonal antibody pembrolizumab, nivolumab, etc after at least 18 weeks; NOTE: This treatment could have been at any time prior to registration 